Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2026)

Xeris Biopharma Holdings has reported Return on Capital Employed for 6 years, with the latest figure at 13.34% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 2337.0% year-over-year to 13.34%; the trailing twelve-month figure through Mar 2026 stood at 13.34% (up 2337.0% YoY), and the FY2025 full-year result was 10.22%, up 2534.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 13.34%, up from 9.31% in the prior quarter.
• The five-year high for Return on Capital Employed was 13.34% in Q1 2026, with the low at 50.09% in Q1 2022.
• Historically, Return on Capital Employed has averaged 18.91% across 5 years, with a median of 19.13% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed surged 5023 bps — and 2024, when it jumped 127 bps.
• Xeris Biopharma Holdings' Return on Capital Employed stood at 32.76% in 2022, then jumped by 42 bps to 19.13% in 2023, then gained by 21 bps to 15.18% in 2024, then soared by 161 bps to 9.31% in 2025, then jumped by 43 bps to 13.34% in 2026.
• The last three Return on Capital Employed figures came in at 13.34% (Q1 2026), 9.31% (Q4 2025), and 4.15% (Q3 2025), per Business Quant data.